EMA recommends approval of Spikevax for children aged 6 to 11

25 febbraio 2022 – EMA’s human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Spikevax to include use in children aged 6 to 11. The vaccine, developed by Moderna, is already approved for use in adults and children aged 12 and above.

For more information, see here.